XW01X27
XW01X27 — Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Anacaulase-bcdb in Subcu, Extern, New Tech 7
How XW01X27 is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 1Body partThe specific site
- XApproachHow the site was reached
- 2DeviceWhat was left in place, if anything
- 7QualifierA further distinction where one applies
Codes near XW01X27
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013TBIntroduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
- XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
- XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
- XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
- XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
- XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
- XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
- XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
- XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
- XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7